RAI - Thimble Shoals-Newport News in Newport News, Virginia - Dialysis Center

RAI - Thimble Shoals-Newport News is a medicare approved dialysis facility center in Newport News, Virginia and it has 24 dialysis stations. It is located in Newport News City county at 739 Thimble Shoals Blvd, Newport News, VA, 23606. You can reach out to the office of RAI - Thimble Shoals-Newport News at (757) 873-1090. This dialysis clinic is managed and/or owned by Fresenius Medical Care. RAI - Thimble Shoals-Newport News has the following ownership type - Profit. It was first certified by medicare in August, 1990. The medicare id for this facility is 492552 and it accepts patients under medicare ESRD program.

Dialysis Center Profile

NameRAI - Thimble Shoals-Newport News
Location739 Thimble Shoals Blvd, Newport News, Virginia
No. of Dialysis Stations 24
Medicare ID492552
Managed ByFresenius Medical Care
Ownership TypeProfit
Late Shifts No

Contact Information


739 Thimble Shoals Blvd, Newport News, Virginia, 23606
(757) 873-1090

News Archive

FDA CDER assigned for pre-market review of CorMedix's Neutrolin

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced that on September 15, 2011, the U.S. Food and Drug Administration advised CorMedix, that the Center for Drug Evaluation and Research has been assigned as the lead agency for the pre-market review of Neutrolin.

Metabolic characteristics of CRPC may open new avenues for treatment

Advanced prostate cancer is usually treated by removing androgen, the male hormone that helps it grow. Although initially effective, this treatment often leads to the tumor becoming castration resistant- a lethal condition.

Delayed loss of nerve cells in the brain linked to symptoms of depression following stroke

Several weeks after mild brain ischemia, mice display a depressive-like syndrome characterized by increased anxiety, inactivity and "cheerlessness". These symptoms of depression following a stroke are associated with the delayed loss of nerve cells in the brain's reward regions. This is the major finding of a study published in the current issue of Biological Psychiatry.

GTC Biotherapeutics achieves high-level production of TG20 monoclonal antibody

GTC Biotherapeutics, Inc. announced that it has achieved high-level production of TG20; an anti-CD20 monoclonal antibody (MAb). The TG20 MAb, which is produced in the milk of transgenic goats, is being co-developed by GTC and LFB as part of the LFB-GTC joint venture.

Read more Medical News

› Verified 9 days ago


Map and Direction



NPI Associated with this Dialysis Facility:

Dialysis Facilities may have multiple NPI numbers. We have found possible NPI number/s associated with RAI - Thimble Shoals-Newport News from NPPES records by matching pattern on the basis of name, address, phone number etc. Please use this information accordingly.

NPI Number1285746735
Organization NameRai-thimble Shoals-newport News
Doing Business AsRai Care Centers Of Virginia I, Llc
Address739 Thimble Shoals Blvd Newport News, Virginia, 23606
Phone Number(757) 873-1090

News Archive

FDA CDER assigned for pre-market review of CorMedix's Neutrolin

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced that on September 15, 2011, the U.S. Food and Drug Administration advised CorMedix, that the Center for Drug Evaluation and Research has been assigned as the lead agency for the pre-market review of Neutrolin.

Metabolic characteristics of CRPC may open new avenues for treatment

Advanced prostate cancer is usually treated by removing androgen, the male hormone that helps it grow. Although initially effective, this treatment often leads to the tumor becoming castration resistant- a lethal condition.

Delayed loss of nerve cells in the brain linked to symptoms of depression following stroke

Several weeks after mild brain ischemia, mice display a depressive-like syndrome characterized by increased anxiety, inactivity and "cheerlessness". These symptoms of depression following a stroke are associated with the delayed loss of nerve cells in the brain's reward regions. This is the major finding of a study published in the current issue of Biological Psychiatry.

GTC Biotherapeutics achieves high-level production of TG20 monoclonal antibody

GTC Biotherapeutics, Inc. announced that it has achieved high-level production of TG20; an anti-CD20 monoclonal antibody (MAb). The TG20 MAb, which is produced in the milk of transgenic goats, is being co-developed by GTC and LFB as part of the LFB-GTC joint venture.

Read more Medical News

› Verified 9 days ago


Survey of Patient's Experiences

Nephrologists Performance Ratings

Experience MeasureProviderNational Avg.
Patients who reported that nephrologists always communicated and cared for them.67%67%
Patients who reported that nephrologists usually communicated and cared for them.17%15%
Patients who reported that nephrologists sometimes or never communicated and cared for them.16%18%
Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible).62%60%
Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible).27%26%
Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible).11%14%

News Archive

FDA CDER assigned for pre-market review of CorMedix's Neutrolin

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced that on September 15, 2011, the U.S. Food and Drug Administration advised CorMedix, that the Center for Drug Evaluation and Research has been assigned as the lead agency for the pre-market review of Neutrolin.

Metabolic characteristics of CRPC may open new avenues for treatment

Advanced prostate cancer is usually treated by removing androgen, the male hormone that helps it grow. Although initially effective, this treatment often leads to the tumor becoming castration resistant- a lethal condition.

Delayed loss of nerve cells in the brain linked to symptoms of depression following stroke

Several weeks after mild brain ischemia, mice display a depressive-like syndrome characterized by increased anxiety, inactivity and "cheerlessness". These symptoms of depression following a stroke are associated with the delayed loss of nerve cells in the brain's reward regions. This is the major finding of a study published in the current issue of Biological Psychiatry.

GTC Biotherapeutics achieves high-level production of TG20 monoclonal antibody

GTC Biotherapeutics, Inc. announced that it has achieved high-level production of TG20; an anti-CD20 monoclonal antibody (MAb). The TG20 MAb, which is produced in the milk of transgenic goats, is being co-developed by GTC and LFB as part of the LFB-GTC joint venture.

Read more Medical News

› Verified 9 days ago

Dialysis Center Staff Performance Ratings

Experience MeasureProviderNational Avg.
Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible.57%62%
Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible.25%20%
Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free.18%18%
Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible).58%62%
Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible).35%26%
Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible).7%12%

News Archive

FDA CDER assigned for pre-market review of CorMedix's Neutrolin

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced that on September 15, 2011, the U.S. Food and Drug Administration advised CorMedix, that the Center for Drug Evaluation and Research has been assigned as the lead agency for the pre-market review of Neutrolin.

Metabolic characteristics of CRPC may open new avenues for treatment

Advanced prostate cancer is usually treated by removing androgen, the male hormone that helps it grow. Although initially effective, this treatment often leads to the tumor becoming castration resistant- a lethal condition.

Delayed loss of nerve cells in the brain linked to symptoms of depression following stroke

Several weeks after mild brain ischemia, mice display a depressive-like syndrome characterized by increased anxiety, inactivity and "cheerlessness". These symptoms of depression following a stroke are associated with the delayed loss of nerve cells in the brain's reward regions. This is the major finding of a study published in the current issue of Biological Psychiatry.

GTC Biotherapeutics achieves high-level production of TG20 monoclonal antibody

GTC Biotherapeutics, Inc. announced that it has achieved high-level production of TG20; an anti-CD20 monoclonal antibody (MAb). The TG20 MAb, which is produced in the milk of transgenic goats, is being co-developed by GTC and LFB as part of the LFB-GTC joint venture.

Read more Medical News

› Verified 9 days ago

Overall Dialysis Center Performance Ratings

Experience MeasureProviderNational Avg.
Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. 80%80%
Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them.20%20%
Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible).69%68%
Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible).28%20%
Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible).3%12%

News Archive

FDA CDER assigned for pre-market review of CorMedix's Neutrolin

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced that on September 15, 2011, the U.S. Food and Drug Administration advised CorMedix, that the Center for Drug Evaluation and Research has been assigned as the lead agency for the pre-market review of Neutrolin.

Metabolic characteristics of CRPC may open new avenues for treatment

Advanced prostate cancer is usually treated by removing androgen, the male hormone that helps it grow. Although initially effective, this treatment often leads to the tumor becoming castration resistant- a lethal condition.

Delayed loss of nerve cells in the brain linked to symptoms of depression following stroke

Several weeks after mild brain ischemia, mice display a depressive-like syndrome characterized by increased anxiety, inactivity and "cheerlessness". These symptoms of depression following a stroke are associated with the delayed loss of nerve cells in the brain's reward regions. This is the major finding of a study published in the current issue of Biological Psychiatry.

GTC Biotherapeutics achieves high-level production of TG20 monoclonal antibody

GTC Biotherapeutics, Inc. announced that it has achieved high-level production of TG20; an anti-CD20 monoclonal antibody (MAb). The TG20 MAb, which is produced in the milk of transgenic goats, is being co-developed by GTC and LFB as part of the LFB-GTC joint venture.

Read more Medical News

› Verified 9 days ago

Patient Distribution

Anemia Management

Dialysis patients with Hemoglobin data64
Medicare patients who had average hemoglobin (hgb) less than 10 g/dL13

News Archive

FDA CDER assigned for pre-market review of CorMedix's Neutrolin

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced that on September 15, 2011, the U.S. Food and Drug Administration advised CorMedix, that the Center for Drug Evaluation and Research has been assigned as the lead agency for the pre-market review of Neutrolin.

Metabolic characteristics of CRPC may open new avenues for treatment

Advanced prostate cancer is usually treated by removing androgen, the male hormone that helps it grow. Although initially effective, this treatment often leads to the tumor becoming castration resistant- a lethal condition.

Delayed loss of nerve cells in the brain linked to symptoms of depression following stroke

Several weeks after mild brain ischemia, mice display a depressive-like syndrome characterized by increased anxiety, inactivity and "cheerlessness". These symptoms of depression following a stroke are associated with the delayed loss of nerve cells in the brain's reward regions. This is the major finding of a study published in the current issue of Biological Psychiatry.

GTC Biotherapeutics achieves high-level production of TG20 monoclonal antibody

GTC Biotherapeutics, Inc. announced that it has achieved high-level production of TG20; an anti-CD20 monoclonal antibody (MAb). The TG20 MAb, which is produced in the milk of transgenic goats, is being co-developed by GTC and LFB as part of the LFB-GTC joint venture.

Read more Medical News

› Verified 9 days ago

Dialysis Adequacy

Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.

  • Hemodialysis
    Adult patients getting regular hemodialysis at the center104
    Adult patient months included in Kt/V greater than or equal to 1.2906
    Percentage of adult patients getting regular hemodialysis at the center99
    Percentage of pediatric patients getting regular hemodialysis at the center

    News Archive

    FDA CDER assigned for pre-market review of CorMedix's Neutrolin

    CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced that on September 15, 2011, the U.S. Food and Drug Administration advised CorMedix, that the Center for Drug Evaluation and Research has been assigned as the lead agency for the pre-market review of Neutrolin.

    Metabolic characteristics of CRPC may open new avenues for treatment

    Advanced prostate cancer is usually treated by removing androgen, the male hormone that helps it grow. Although initially effective, this treatment often leads to the tumor becoming castration resistant- a lethal condition.

    Delayed loss of nerve cells in the brain linked to symptoms of depression following stroke

    Several weeks after mild brain ischemia, mice display a depressive-like syndrome characterized by increased anxiety, inactivity and "cheerlessness". These symptoms of depression following a stroke are associated with the delayed loss of nerve cells in the brain's reward regions. This is the major finding of a study published in the current issue of Biological Psychiatry.

    GTC Biotherapeutics achieves high-level production of TG20 monoclonal antibody

    GTC Biotherapeutics, Inc. announced that it has achieved high-level production of TG20; an anti-CD20 monoclonal antibody (MAb). The TG20 MAb, which is produced in the milk of transgenic goats, is being co-developed by GTC and LFB as part of the LFB-GTC joint venture.

    Read more Medical News

    › Verified 9 days ago

  • Peritoneal Dialysis
    Adult patients getting regular peritoneal dialysis at the center27
    Adult patient months included in Kt/V greater than or equal to 1.7233
    Percentage of adult patients getting regular peritoneal dialysis at the center97
    Percentage of pediatric patients getting regular peritoneal dialysis at the center

    News Archive

    FDA CDER assigned for pre-market review of CorMedix's Neutrolin

    CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced that on September 15, 2011, the U.S. Food and Drug Administration advised CorMedix, that the Center for Drug Evaluation and Research has been assigned as the lead agency for the pre-market review of Neutrolin.

    Metabolic characteristics of CRPC may open new avenues for treatment

    Advanced prostate cancer is usually treated by removing androgen, the male hormone that helps it grow. Although initially effective, this treatment often leads to the tumor becoming castration resistant- a lethal condition.

    Delayed loss of nerve cells in the brain linked to symptoms of depression following stroke

    Several weeks after mild brain ischemia, mice display a depressive-like syndrome characterized by increased anxiety, inactivity and "cheerlessness". These symptoms of depression following a stroke are associated with the delayed loss of nerve cells in the brain's reward regions. This is the major finding of a study published in the current issue of Biological Psychiatry.

    GTC Biotherapeutics achieves high-level production of TG20 monoclonal antibody

    GTC Biotherapeutics, Inc. announced that it has achieved high-level production of TG20; an anti-CD20 monoclonal antibody (MAb). The TG20 MAb, which is produced in the milk of transgenic goats, is being co-developed by GTC and LFB as part of the LFB-GTC joint venture.

    Read more Medical News

    › Verified 9 days ago

Mineral and Bone Disorder

An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at RAI - Thimble Shoals-Newport News with elevated calcium levels.

Patients with hypercalcemia137
Hypercalcemia patient months1208
Patients with Serumphosphor148
Patients with Serumphosphor less than 3.5 mg/dL10
Patients with Serumphosphor from 3.5 to 4.5 mg/dL30
Patients with Serumphosphor from 4.6 to 5.5 mg/dL33
Patients with Serumphosphor from 5.6 to 7 mg/dL19
Patients with Serumphosphor greater than 7 mg/dL9

News Archive

FDA CDER assigned for pre-market review of CorMedix's Neutrolin

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced that on September 15, 2011, the U.S. Food and Drug Administration advised CorMedix, that the Center for Drug Evaluation and Research has been assigned as the lead agency for the pre-market review of Neutrolin.

Metabolic characteristics of CRPC may open new avenues for treatment

Advanced prostate cancer is usually treated by removing androgen, the male hormone that helps it grow. Although initially effective, this treatment often leads to the tumor becoming castration resistant- a lethal condition.

Delayed loss of nerve cells in the brain linked to symptoms of depression following stroke

Several weeks after mild brain ischemia, mice display a depressive-like syndrome characterized by increased anxiety, inactivity and "cheerlessness". These symptoms of depression following a stroke are associated with the delayed loss of nerve cells in the brain's reward regions. This is the major finding of a study published in the current issue of Biological Psychiatry.

GTC Biotherapeutics achieves high-level production of TG20 monoclonal antibody

GTC Biotherapeutics, Inc. announced that it has achieved high-level production of TG20; an anti-CD20 monoclonal antibody (MAb). The TG20 MAb, which is produced in the milk of transgenic goats, is being co-developed by GTC and LFB as part of the LFB-GTC joint venture.

Read more Medical News

› Verified 9 days ago

Vascular Access

The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.

Patients included in arterial venous fistula and catheter summaries 119
Patient months included in arterial venous fistula and catheter summaries 796
Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment70
Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer16

News Archive

FDA CDER assigned for pre-market review of CorMedix's Neutrolin

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced that on September 15, 2011, the U.S. Food and Drug Administration advised CorMedix, that the Center for Drug Evaluation and Research has been assigned as the lead agency for the pre-market review of Neutrolin.

Metabolic characteristics of CRPC may open new avenues for treatment

Advanced prostate cancer is usually treated by removing androgen, the male hormone that helps it grow. Although initially effective, this treatment often leads to the tumor becoming castration resistant- a lethal condition.

Delayed loss of nerve cells in the brain linked to symptoms of depression following stroke

Several weeks after mild brain ischemia, mice display a depressive-like syndrome characterized by increased anxiety, inactivity and "cheerlessness". These symptoms of depression following a stroke are associated with the delayed loss of nerve cells in the brain's reward regions. This is the major finding of a study published in the current issue of Biological Psychiatry.

GTC Biotherapeutics achieves high-level production of TG20 monoclonal antibody

GTC Biotherapeutics, Inc. announced that it has achieved high-level production of TG20; an anti-CD20 monoclonal antibody (MAb). The TG20 MAb, which is produced in the milk of transgenic goats, is being co-developed by GTC and LFB as part of the LFB-GTC joint venture.

Read more Medical News

› Verified 9 days ago

Hospitalization Rate

The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.

Standard Hospitalization Summary Ratio(SHR) YearJanuary, 2016 - December, 2016
Patients in facility's Hospitalization Summary109
Hospitalization Rate in facility156.5 (As Expected)
Hospitalization Rate: Upper Confidence Limit263.7
Hospitalization Rate: Lower Confidence Limit100.5

News Archive

FDA CDER assigned for pre-market review of CorMedix's Neutrolin

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced that on September 15, 2011, the U.S. Food and Drug Administration advised CorMedix, that the Center for Drug Evaluation and Research has been assigned as the lead agency for the pre-market review of Neutrolin.

Metabolic characteristics of CRPC may open new avenues for treatment

Advanced prostate cancer is usually treated by removing androgen, the male hormone that helps it grow. Although initially effective, this treatment often leads to the tumor becoming castration resistant- a lethal condition.

Delayed loss of nerve cells in the brain linked to symptoms of depression following stroke

Several weeks after mild brain ischemia, mice display a depressive-like syndrome characterized by increased anxiety, inactivity and "cheerlessness". These symptoms of depression following a stroke are associated with the delayed loss of nerve cells in the brain's reward regions. This is the major finding of a study published in the current issue of Biological Psychiatry.

GTC Biotherapeutics achieves high-level production of TG20 monoclonal antibody

GTC Biotherapeutics, Inc. announced that it has achieved high-level production of TG20; an anti-CD20 monoclonal antibody (MAb). The TG20 MAb, which is produced in the milk of transgenic goats, is being co-developed by GTC and LFB as part of the LFB-GTC joint venture.

Read more Medical News

› Verified 9 days ago

Readmission Rate

The rate of readmission show you whether patients who were being treated regularly at RAI - Thimble Shoals-Newport News were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.

Standard Readmission Summary Ratio(SRR) YearJanuary, 2016 - December, 2016
Readmission Rate in facility37.7 (Worse than Expected)
Readmission Rate: Upper Confidence Limit48.7
Readmission Rate: Lower Confidence Limit27

News Archive

FDA CDER assigned for pre-market review of CorMedix's Neutrolin

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced that on September 15, 2011, the U.S. Food and Drug Administration advised CorMedix, that the Center for Drug Evaluation and Research has been assigned as the lead agency for the pre-market review of Neutrolin.

Metabolic characteristics of CRPC may open new avenues for treatment

Advanced prostate cancer is usually treated by removing androgen, the male hormone that helps it grow. Although initially effective, this treatment often leads to the tumor becoming castration resistant- a lethal condition.

Delayed loss of nerve cells in the brain linked to symptoms of depression following stroke

Several weeks after mild brain ischemia, mice display a depressive-like syndrome characterized by increased anxiety, inactivity and "cheerlessness". These symptoms of depression following a stroke are associated with the delayed loss of nerve cells in the brain's reward regions. This is the major finding of a study published in the current issue of Biological Psychiatry.

GTC Biotherapeutics achieves high-level production of TG20 monoclonal antibody

GTC Biotherapeutics, Inc. announced that it has achieved high-level production of TG20; an anti-CD20 monoclonal antibody (MAb). The TG20 MAb, which is produced in the milk of transgenic goats, is being co-developed by GTC and LFB as part of the LFB-GTC joint venture.

Read more Medical News

› Verified 9 days ago

Infection Rate

Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at RAI - Thimble Shoals-Newport News get infections in their blood each year compared to the number of infections expected for the center based on the national average.

Standard Infection Summary Ratio(SIR) YearJanuary, 2016 - December, 2016
Infection Rate in facility.89 (As Expected)
SIR: Upper Confidence Limit1.76
SIR: Lower Confidence Limit.39

News Archive

FDA CDER assigned for pre-market review of CorMedix's Neutrolin

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced that on September 15, 2011, the U.S. Food and Drug Administration advised CorMedix, that the Center for Drug Evaluation and Research has been assigned as the lead agency for the pre-market review of Neutrolin.

Metabolic characteristics of CRPC may open new avenues for treatment

Advanced prostate cancer is usually treated by removing androgen, the male hormone that helps it grow. Although initially effective, this treatment often leads to the tumor becoming castration resistant- a lethal condition.

Delayed loss of nerve cells in the brain linked to symptoms of depression following stroke

Several weeks after mild brain ischemia, mice display a depressive-like syndrome characterized by increased anxiety, inactivity and "cheerlessness". These symptoms of depression following a stroke are associated with the delayed loss of nerve cells in the brain's reward regions. This is the major finding of a study published in the current issue of Biological Psychiatry.

GTC Biotherapeutics achieves high-level production of TG20 monoclonal antibody

GTC Biotherapeutics, Inc. announced that it has achieved high-level production of TG20; an anti-CD20 monoclonal antibody (MAb). The TG20 MAb, which is produced in the milk of transgenic goats, is being co-developed by GTC and LFB as part of the LFB-GTC joint venture.

Read more Medical News

› Verified 9 days ago

Transfusion Summary

Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether RAI - Thimble Shoals-Newport News's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.

Standard Transfusion Summary Ratio (STrR) Year January, 2016 - December, 2016
Patients in facility's Transfusion Summary 94
Transfusion Rate in facility19.2 (As Expected)
Transfusion Rate: Upper Confidence Limit55.6
Transfusion Rate: Lower Confidence Limit7.5

News Archive

FDA CDER assigned for pre-market review of CorMedix's Neutrolin

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced that on September 15, 2011, the U.S. Food and Drug Administration advised CorMedix, that the Center for Drug Evaluation and Research has been assigned as the lead agency for the pre-market review of Neutrolin.

Metabolic characteristics of CRPC may open new avenues for treatment

Advanced prostate cancer is usually treated by removing androgen, the male hormone that helps it grow. Although initially effective, this treatment often leads to the tumor becoming castration resistant- a lethal condition.

Delayed loss of nerve cells in the brain linked to symptoms of depression following stroke

Several weeks after mild brain ischemia, mice display a depressive-like syndrome characterized by increased anxiety, inactivity and "cheerlessness". These symptoms of depression following a stroke are associated with the delayed loss of nerve cells in the brain's reward regions. This is the major finding of a study published in the current issue of Biological Psychiatry.

GTC Biotherapeutics achieves high-level production of TG20 monoclonal antibody

GTC Biotherapeutics, Inc. announced that it has achieved high-level production of TG20; an anti-CD20 monoclonal antibody (MAb). The TG20 MAb, which is produced in the milk of transgenic goats, is being co-developed by GTC and LFB as part of the LFB-GTC joint venture.

Read more Medical News

› Verified 9 days ago

Survival Summary

The rate of mortality show you whether patients who were being treated regularly at RAI - Thimble Shoals-Newport News lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.

Standard Survival Summary Ratio(SIR) YearJanuary, 2013 - December, 2016
Patients in facility's Survival Summary619
Mortality Rate in facility19.8 (As Expected)
Mortality Rate: Upper Confidence Limit24.7
Mortality Rate: Lower Confidence Limit15.7

News Archive

FDA CDER assigned for pre-market review of CorMedix's Neutrolin

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced that on September 15, 2011, the U.S. Food and Drug Administration advised CorMedix, that the Center for Drug Evaluation and Research has been assigned as the lead agency for the pre-market review of Neutrolin.

Metabolic characteristics of CRPC may open new avenues for treatment

Advanced prostate cancer is usually treated by removing androgen, the male hormone that helps it grow. Although initially effective, this treatment often leads to the tumor becoming castration resistant- a lethal condition.

Delayed loss of nerve cells in the brain linked to symptoms of depression following stroke

Several weeks after mild brain ischemia, mice display a depressive-like syndrome characterized by increased anxiety, inactivity and "cheerlessness". These symptoms of depression following a stroke are associated with the delayed loss of nerve cells in the brain's reward regions. This is the major finding of a study published in the current issue of Biological Psychiatry.

GTC Biotherapeutics achieves high-level production of TG20 monoclonal antibody

GTC Biotherapeutics, Inc. announced that it has achieved high-level production of TG20; an anti-CD20 monoclonal antibody (MAb). The TG20 MAb, which is produced in the milk of transgenic goats, is being co-developed by GTC and LFB as part of the LFB-GTC joint venture.

Read more Medical News

› Verified 9 days ago


Dialysis Facility in Newport News, VA

RAI - Thimble Shoals-Newport News
Location: 739 Thimble Shoals Blvd, Newport News, Virginia, 23606
Phone: (757) 873-1090
Davita - Newport News
Location: 711 79th Street, Newport News, Virginia, 23605
Phone: (757) 245-8090
Peninsula Dialysis Center
Location: 716 Denbigh Blvd, Newport News, Virginia, 23608
Phone: (757) 875-1125
RAI - Chesapeake-Newport News
Location: 225 Chesapeake Avenue, Newport News, Virginia, 23607
Phone: (757) 247-4080
Jefferson Avenue Dialysis
Location: 11234 Jefferson Ave, Newport News, Virginia, 23601
Phone: (757) 595-6167

News Archive

FDA CDER assigned for pre-market review of CorMedix's Neutrolin

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced that on September 15, 2011, the U.S. Food and Drug Administration advised CorMedix, that the Center for Drug Evaluation and Research has been assigned as the lead agency for the pre-market review of Neutrolin.

Metabolic characteristics of CRPC may open new avenues for treatment

Advanced prostate cancer is usually treated by removing androgen, the male hormone that helps it grow. Although initially effective, this treatment often leads to the tumor becoming castration resistant- a lethal condition.

Delayed loss of nerve cells in the brain linked to symptoms of depression following stroke

Several weeks after mild brain ischemia, mice display a depressive-like syndrome characterized by increased anxiety, inactivity and "cheerlessness". These symptoms of depression following a stroke are associated with the delayed loss of nerve cells in the brain's reward regions. This is the major finding of a study published in the current issue of Biological Psychiatry.

GTC Biotherapeutics achieves high-level production of TG20 monoclonal antibody

GTC Biotherapeutics, Inc. announced that it has achieved high-level production of TG20; an anti-CD20 monoclonal antibody (MAb). The TG20 MAb, which is produced in the milk of transgenic goats, is being co-developed by GTC and LFB as part of the LFB-GTC joint venture.

Read more Medical News

› Verified 9 days ago


Find & Compare Providers Near You: Find and compare doctors, nursing homes, hospitals, and other health care providers in your area that accept Medicare. Get information like: Find a doctor or clinician that accepts Medicare near you.

Doctors and clinicians: Doctors and clinicians include doctors, clinicians and groups who are qualified to practice in many specialties. Each specialty focuses on certain parts of the body, periods of life, conditions, or primary care. The doctors, clinicians, and groups listed here typically work in an office or clinic setting. Also those who currently accept Medicare are included.

Hospitals: Find information about Medicare-certified hospitals and long-term care hospitals in your area, including Veterans Administration medical centers and military hospitals, across the country. Long-term care hospitals serve critically ill and medically complex patients who require extended hospital care.

Data provided: Information on www.medicareusa.org is built using open data sources published by Centers for Medicare & Medicaid Services (CMS) under Freedom of Information Act (FOIA).

© 2024 MedicareUsa. All rights reserved. Maintained by the Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services.